Stock 300006 CHONGQING LUMMY PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Chongqing Lummy Pharmaceutical Co., Ltd.

Equities

300006

CNE100000H10

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-14 pm EDT 		5-day change 1st Jan Change
2.76 CNY -6.12% Intraday chart for Chongqing Lummy Pharmaceutical Co., Ltd. -8.61% -25.81%
Mar. 22 Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 18 Lummy Pharma Gets Nod to Raise Dosage of Gastric Drug MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lummy Pharma Gets Nod to Raise Dosage of Gastric Drug
MT
Lummy Pharma Gets Nod to Market Nicorandil
MT
Lummy Pharmaceutical's Ramosetron Hydrochloride Injection Passes Regulatory Evaluation
MT
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Lummy Pharmaceutical's Unit Gets Nod to Trial Ovarian Cancer Drug; Shares Surge 20%
MT
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Chongqing Lummy Pharmaceutical's Cancer Drug Passes Regulatory Evaluation
MT
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Chongqing Lummy Pharmaceutical Co., Ltd. announced that it expects to receive CNY 300 million in funding
CI
Lummy Pharma Unit Gets Regulatory Nod in China for Liver Cirrhosis Drug
MT
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Chongqing Lummy Pharmaceutical Co., Ltd.(XSEC:300006) dropped from S&P Global BMI Index
CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Chengdu Xindu District Cundetang Pharmacy Co., Ltd. announced that it has received $7.800000 million in funding from KIP China, Chongqing Lummy Pharmaceutical Co., Ltd. and another investor.
CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
Chongqing Lummy Pharmaceutical Co., Ltd.(XSEC:300006) added to S&P Global BMI Index
CI
Chongqing Lummy Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 300006 Stock
  4. News Chongqing Lummy Pharmaceutical Co., Ltd.